newsfilter
← Latest News
GlobeNewswire·

Talaris Therapeutics Announces Third Quarter 2021 Financial Results and Provides Business Update

Provided initial clinical update from its Phase 3 (FREEDOM-1) clinical trial evaluating FCR001 in living donor kidney transplant patients Initiated Phase 2 (FREEDOM-2) clinical trial for FCR001 in delayed tolerance induction patients BOSTON and LOU